Does pretreatment human papillomavirus (HPV) titers predict radiation response and survival outcomes in cancer cervix?-A pilot study

Gynecologic Oncology

Volumn 103, Issue 1, 2006, Pages 100-105

  Datta, Niloy R ^a   Kumar, Piyush ^a   Singh, Shalini ^a   Gupta, Dinesh ^b   Srivastava, Anurita ^a   Dhole, Tapankumar N ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

^b National Clinical Reference Lab   (India)

Author keywords

Cancer cervix; Human papillomavirus; Predictor; Radiotherapy; Survival

Indexed keywords

ADULT; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; DISEASE FREE SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIATION RESPONSE; UTERINE CERVIX CANCER; VIRUS LOAD; WART VIRUS;

BRACHYTHERAPY; CARCINOMA, SQUAMOUS CELL; DNA, VIRAL; FEMALE; HUMANS; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PILOT PROJECTS; PREDICTIVE VALUE OF TESTS; SURVIVAL RATE; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

EID: 33748570855     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2006.01.058     Document Type: Article

References (29)

1. Vizcaino A.P., Moreno V., Bosch F.X., Munoz N., Barros-Dios X.M., Borras J., et al. International trends in incidence of cervical cancer: II. Squamous cell carcinoma. Int. J. Cancer 86 (2000) 429-435
2. Schiffman M.H., Bauer H.M., Hoover R.N., Glass A.G., Cadell D.M., Rush B.B., et al. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J. Natl. Cancer Inst. 85 (1993) 958-964
3. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189 (1999) 12-19
4. Datta N.R., Pasricha R., Singh U., and Srivastava A. Predictors of survival end points in patients of cancer cervix on long term follow up: inferences and implications from an audit of patients treated with a specific radiotherapy protocol. Clin. Oncol. 16 (2004) 536-542
5. Riou G., Favre M., Jeannel D., Bourhis J., Le Doussal V., and Orth G. Association between poor prognosis in early stage invasive cervical carcinomas and non-detection of HPV DNA. Lancet 335 (1990) 1171-1174
6. Ikenberg H., Sauerbrei W., Schotttmuller U., Spitz C., and Pfleiderer A. Human papillomavirus DNA in cervical carcinoma-correlation with clinical data and influence on prognosis. Int. J. Cancer 59 (1994) 322-326
7. Rose B.R., Thompson C.H., Cossart Y.E., Elliot P.E., and Tattersall M.H. Papillomavirus DNA and prognosis in cervical cancer. Lancet 337 (1991) 489
8. Harima Y., Sawada S., Nagata K., Sougawa M., and Ohnishi T. Human papilloma virus (HPV) DNA associated with prognosis of cervical cancer after radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 52 (2002) 1345-1351
9. Lorincz A.T. Hybrid capture method for detection of human papillomavirus DNA in clinical specimens: a tool for clinical management of equivocal Pap smears and population screening. J Obstet. Gynaecol. Res. 22 (1996) 629-636
10. Sankaranarayana R., Chatterji R., Shastri S.S., Wesley R.S., Basu P., Mahe C., et al. Accuracy of human papillomavirus testing in primary screening of cervical neoplasia: results from a multicenter study in India. Int. J. Cancer 112 (2004) 341-347
11. Brinton L.A. Epidemiology of cervical cancer-overview. In: Munoz N., Bosch F.X., Shah K.V., and Meheus A. (Eds). The Epidemiology of Human Papillomavirus and Cervical Cancer (1992), IARC, Lyon 3-23
12. Hubbard R.A. Human Papillomavirus testing methods. Arch. Pathol. Lab. Med. 127 (2003) 940-945
13. Bolick D.R., Bolick R.E., Coates F., Daniels C.M., Juretich M.B., Lin K.K., et al. Laboratory implementation of human papillomavirus testing. Arch. Pathol. Lab. Med. 127 (2003) 984-990
14. Castle P.E., Lorincz A.T., Mielzynska-Lohnas I., Scott D.R., Glass A.G., Sherman M.E., et al. Results of human papillomavirus DNA testing with the hybrid capture 2 assay are reproducible. J. Clin. Microbiol. 40 (2002) 1088-1090
15. Belinson J., Qiao Y.L., Pretorius R., Zhang W.H., Elson P., Li L., et al. Shanxi province cervical cancer screening study: a cross sectional comparative trial of multiple techniques to detect cervical neoplasia. Gynecol. Oncol. 83 (2001) 439-444
16. Wright Jr. T.C., Denny L., Kuhn L., Pollack A., and Lorincz A. HPV DNA testing of self collected vaginal samples compared with cytologic screening to detect cervical cancer. JAMA 283 (2000) 81-86
17. Schiffman M., Herrero R., Hildesheim A., Scherman M.E., Bratti M., Wacholder S., et al. HPV DNA testing in cervical cancer screening: results from women in a high risk province of Costa Rica. JAMA 283 (2000) 87-93
18. Kuhn L., Denny L., Pollack A., Lorincz A., Richart R.M., Wright T.C., et al. Human papillomavirus DNA testing for cervical cancer screening in low resource settings. J. Natl. Cancer Inst. 92 (2000) 818-825
19. Bozzetti M., Nonnenmacher B., Mielzinska I.I., Villa L., Lorincz A., Breitenbach V.V., et al. Comparison between hybrid capture II and polymerase chain reaction results among women at low risk for cervical cancer. Ann. Epidemiol. 10 (2000) 466
20. Lombard I., Vincent-Salomon A., Validire P., Zafrani B., de la Rochefordiere A., Clough K., et al. Human papillomavirus genotype as a major determinant of the course of cervical cancer. J. Clin. Oncol. 16 (1998) 2613-2619
21. King L.A., Tase T., Twiggs L.B., Okagaki T., Savage J.E., Adcock L.L., et al. Prognostic significance of the presence of human papillomavirus DNA in patients with invasive carcinoma of the cervix. Cancer 63 (1989) 897-900
22. Meanwell C.A., Cox M.F., Blackledge G., and Maitlanda N.J. HPV16 DNA in normal and malignant cervical epithelium: implications for the aetiology and behaviour of cervical neoplasia. Lancet 1 (1987) 703-707
23. van Bommel P.F., van den Brule A.J., Helmerhorst T.J., Gallee M.P., Gaarenstoom K.N., Walboomers J.M., et al. HPV DNA presence and HPV genotypes as prognostic factors in low stage squamous cell cervical cancer. Gynecol. Oncol. 48 (1993) 333-337
24. Viladiu P., Bosch F.X., Castellsagué X., Munoz N., Escriba J.M., Hamsikova E., et al. Human papillomavirus DNA and antibodies to human papillomaviruses 16 E2, L2 and E7 peptides as predictors of survival in patients with squamous cell cervical cancer. J. Clin. Oncol. 15 (1997) 610-619
25. Kristensen G.B., Karlsen F., Jenkins A., Kærn J., Abeler V.M., and Tropé C.G. Human papilloma virus has no prognostic significance in cervical carcinoma. Eur. J. Cancer 32A (1996) 1349-1353
26. Santin A.D., Hermonat P.L., Ravaggi A., Chiriva-Internati M., Pecorelli S., and Parham G.P. Radiation-enhanced expression of E6/E7 transforming oncogenes of human papillomavirus-16 in human cervical carcinoma. Cancer 83 (1998) 2346-2352
27. Higgins G.D., Davy M., Roder D., Uzelin D.M., Phillips G.E., and Burrell C.J. Increased age and mortality associated with cervical carcinomas negative for human papilloma virus RNA. Lancet 338 (1991) 910-913
28. Ishikawa H., Mitsuhashi N., Sakurai H., Maebayashi K., and Niibe H. The effects of p53 status and human papillomavirus infection on the clinical outcome of patients with stage IIIB cervical carcinoma treated with radiation therapy alone. Cancer 91 (2001) 80-89
29. Saxena A., Yashar C., Taylor D.D., and Gercel-Taylor C. Cellular response to chemotherapy and radiation in cervical cancer. Am. J. Obstet. Gynecol. 192 (2005) 1399-1403